Product Introduction

HESI30/0.4 is a further optimization on the basis of HES200/0.5, which not only maintains the same dilatation effect as HES200/0.5, but also improves renal clearance, reduces plasma and tissue accumulation and the influence on coagulation function. In addition, it also breaks the dose limit of HES200/0.5, and can be used in critically ill patients and infants, and is a more ideal colloidal solution. The average relative molecular weight of HESI30/0.4 is 130,000. Compared with HES200/0.5, the distribution of relative molecular weight is more concentrated, which reduces the proportion of large molecules that have adverse effects on hemorheology and coagulation function, and also reduces the proportion of small molecules that are rapidly cleared when their relative molecular weight is lower than the renal odor value. Its substitution level is reduced from 0.5 to 0.4(about 20%) and the substitution mode (C2/C6) is increased from 5:1 to 9:1, ensuring that it can be continuously cleared by the kidneys without plasma accumulation even after multiple dosing. Based on its unique physical and chemical properties, HESI30/0.4 shows a stable and reliable dilatation effect and action duration.

Features

Rapid initial volume effectiveness: Within 30 minutes of infusion, the volume expansion effect is 100%, and the 100% volume effect can be stable for 4-6 hours;

Isovolemic blood replacement, which can maintain blood volume for at least 6 hours;

Rapid clearance by kidney: the body's clearance rate is high, up to 31.4ml/min, and almost completely excreted in 24 hours;

Even with repeated administration, there was no plasma accumulation and tissue accumulation was significantly reduced.